-
SR 11302: Translating AP-1 Biology Into Cancer Strategy
2026-09-18
SR 11302 provides a mechanistically focused route to interrogate AP-1-driven tumor biology without directly activating RAR or RXR. This thought-leadership analysis connects its cancer-cell data with macrophage and TLR4 findings in colitis-associated colorectal cancer, while defining practical assay, translational, and evidence boundaries.
-
EZ Cap™ CPF1/Cas12a mRNA (m1Ψ) Workflow
2026-09-17
EZ Cap™ CPF1/Cas12a mRNA (m1Ψ) supports transient Cas12a expression for research workflows that benefit from a single crRNA, T-rich PAM recognition, and PAM-distal staggered cleavage. This practical guide connects product selection with guide design, delivery optimization, editing quantification, and troubleshooting while separating published evidence from starting recommendations.
-
7-dehydro Cholesterol: Assay Workflows
2026-09-17
Use 7-dehydro Cholesterol to connect DHCR7 activity, UVB-driven vitamin D3 formation, sterol oxidation, and disease-relevant lipid remodeling in one experimental framework. A practical workflow also shows how chemical substrate exposure can complement, but not replace, genetic studies of DHCR7-linked antiviral phenotypes.
-
IBDV VP3 Drives IRF7 Proteasomal Loss
2026-09-16
The 2025 Frontiers in Cellular and Infection Microbiology study identifies IBDV VP3 as a viral factor that suppresses IRF7-dependent type I interferon signaling by promoting IRF7 loss through the proteasome pathway. Its infection, gain-of-function, loss-of-function, and protein-interaction experiments provide a mechanistic framework for understanding how very virulent IBDV evades antiviral defense, while also defining important limits for applying E1 or proteasome perturbation tools.
-
Thapsigargin for Reproducible Cell Assays
2026-09-15
Learn how Thapsigargin (SKU B6614) helps researchers connect SERCA inhibition with calcium signaling, ER stress, apoptosis, and cell viability outcomes. This scenario-based guide covers assay design, optimization, interpretation, and practical product-selection criteria.
-
Hydrocortisone Butyrate: From GR Biology to Delivery
2026-09-15
Hydrocortisone butyrate is more than a glucocorticoid receptor agonist for inflammation assays. This guide connects receptor biology, dermatitis and epidermal models, and PLGA-based delivery research while showing why ester stability and exposure design determine translational interpretation.
-
MK 0893: From Receptor Binding to In Vivo Readouts
2026-09-14
MK 0893 is a glucagon receptor antagonist whose allosteric pharmacology connects nanomolar receptor binding with measurable metabolic effects. This article offers an assay-to-animal framework for interpreting MK 0893 in type 2 diabetes research, with emphasis on endpoint selection, selectivity, and translational limits.
-
N2703 for Causal Cardiac Signaling Assays
2026-09-14
Explore how 3-(1-methylpyrrolidin-2-yl)pyridine (N2703) can be evaluated in mechanism-focused cardiac models without overstating its biology. This guide translates adipose-neural arrhythmia research into rigorous assay design, controls, and interpretation.
-
Structural Insights into CD38 CAR Affinity Tuning
2026-09-13
This iScience study compares how the CAR binders RP02 and 028 engage CD38, revealing distinct epitope geometries, effects on enzymatic activity, and opportunities for rational affinity tuning. Its affinity-attenuated 028R103G design reduced CAR-T fratricide while preserving cytotoxicity against CD38-positive tumor cells, supporting structure-guided optimization of CD38-directed therapy.
-
Gap26 Connexin 43 Mimetic Peptide Guide
2026-09-12
Gap26 is a connexin 43 mimetic peptide that inhibits Cx43 hemichannel and gap junction communication. It supports controlled studies of calcium signaling modulation, ATP release inhibition, vascular smooth muscle research, and gap junction-dependent mitochondrial transfer.
-
DDI2–NFE2L1 Protects Cells from Ferroptosis
2026-09-12
The reference study identifies DDI2-mediated activation of NFE2L1 as an adaptive response that restores proteasome function during ferroptosis. Its combination of site-specific ubiquitylation proteomics, genetic perturbation, and chemical validation shows how failure of this pathway increases proteotoxic stress and ferroptotic cell death.
-
Rotenone Workflows for Mitochondrial Stress Research
2026-09-11
Rotenone provides a controlled way to connect Complex I inhibition with mitochondrial ROS, ATP loss, and regulated cell death. This guide translates those effects into practical cardiac, neuronal, and pathway-focused workflows, with assay controls that help separate pyroptosis, ferroptosis, apoptosis, and autophagy responses.
-
2-NBDG for Mechanistic Glucose Uptake Assays
2026-09-11
Learn how 2-NBDG converts glucose transporter activity into a resolvable fluorescent phenotype and how to interpret it alongside glycolysis, cell-state, and m6A studies. This guide emphasizes assay design for mechanistic cancer metabolism research rather than uptake measurement alone.
-
From Ferroptosis Signals to Cell Viability Decisions
2026-09-10
Mechanistic oncology studies increasingly need phenotypic assays that connect pathway disruption with actual cell fate. This article examines how Calcein AM/PI staining can complement ferroptosis research in triple-negative breast cancer, while clarifying what a dual-fluorescence viability readout can—and cannot—prove.
-
Clasto-Lactacystin β-lactone: A Causal Assay Lens
2026-09-10
Clasto-Lactacystin β-lactone is more than a proteasome inhibitor: it can serve as a causal perturbation tool for distinguishing proteasome-dependent protein loss from upstream regulation. This article applies that logic to viral RIPK3 degradation and broader ubiquitin-proteasome pathway research.